2024-03-20T10:40:10-05:00 2023-06-30 860683059 BEACHFLEISCHMAN PLLC 1985 E RIVER ROAD SUITE 201 TUCSON AZ 85718 990 2022-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1840 E RIVER ROAD 100 TUCSON AZ 85718 KEVIN B PERKINS CFO 5205473440 2024-03-18 1 KEVIN PERKINS 999009999 1 KELLY L MELTZER CPA P00633511 5203214600 2024-03-18 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z DR KLAUS ROMERO 1840 E RIVER ROAD 100 TUCSON AZ 85718 35267282 0 X C-PATH.ORG X 2004 AZ INTERNATIONAL COLLABORATIONS AND NOVEL TOOLS TO ENABLE FASTER DEVELOPMENT OF SAFE MEDICAL PRODUCTS 13 13 176 13 0 0 23061454 23557036 8108029 11292408 6633 403834 0 14004 31176116 35267282 4230463 4623204 0 0 17392416 19471313 0 0 0 7977401 7913861 29600280 32008378 1575836 3258904 19962086 26726645 7937546 11460775 12024540 15265870 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 5965204 1517664 0 RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) - SEE SCHEDULE O 4448188 2402563 0 CURE DRUG REPURPOSING COLLABORATORY (CDRC) - SEE SCHEDULE O 2471751 0 0 CRITICAL PATH FOR RARE NEURODEGENERATIVE DISEASES (CP-RND) - SEE SCHEDULE O 13336642 702977 11306412 CRITICAL PATH INSTITUTE ALSO EXECUTES OTHER PROJECTS AND CONSORTIA IN AREAS INCLUDING THERAPEUTICS FOR THE ATAXIAS, POLYCYSTIC KIDNEY DISORDER, ALZHEIMER'S DISEASE, PARKINSON'S, TB, SICKLE CELL DISEASE, TYPE 1 DIABETES, DUCHENNE MUSCULAR DYSTROPHY, ALPHA-1 ANTITRYPSIN DEFICIENCY, LYSOSOMAL DISEASES, MODEL INFORMED DRUG DEVELOPMENT, PATIENT-REPORTED OUTCOME, ELECTRONIC CLINICAL OUTCOME ASSESSMENT, RARE DISEASE CLINICAL OUTCOME ASSESSMENT, TRANSPLANT THERAPEUTICS, PREDICTIVE SAFETY TESTING, PEDIATRICS, AND OTHERS. 13336642 702977 11306412 26221785 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 40 0 1 176 1 0 1 EI NL 0 0 0 0 0 0 0 0 0 0 X 13 13 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X KEVIN B PERKINS CFO 5205473440 1840 E RIVER ROAD 100 TUCSON AZ 85718 MS KRISTEN SWINGLE COO & PRESIDENT 40.00 X 310147 0 46318 DR KLAUS ROMERO CHIEF SCIENCE OFFICER 40.00 X 241799 0 34990 MR KEVIN PERKINS CHIEF FINANCIAL OFFICER & TREASURER 40.00 X 236942 0 47814 MR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 40.00 X 226150 0 29603 DR STEPHEN COONS SENIOR VICE PRESIDENT THRU 03/31/23 40.00 X 224167 0 28959 DR SUDHIR SIVAKUMARAN VICE PRESIDENT/EXECUTIVE DIRECTOR 40.00 X 208819 0 39798 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 40.00 X 194282 0 30675 DR SERGEY RAKHILIN EXECUTIVE DIRECTOR 40.00 X 190374 0 12440 MS SONYA EREMENCO EXECUTIVE DIRECTOR 40.00 X 190367 0 27355 DR MARCO SCHITO EXECUTIVE DIRECTOR 40.00 X 182025 0 29782 MS TERINA MARTINEZ EXECUTIVE DIRECTOR 40.00 X 182013 0 21789 DR KANWALJIT SINGH EXECUTIVE DIRECTOR 40.00 X 178413 0 34960 MR NICHOLAS KING EXECUTIVE DIRECTOR 40.00 X 173081 0 24543 MR LEWIS BARBIERI CORPORATE SECRETARY 40.00 X 134433 0 24011 MR DANIEL M JORGENSEN CEO/BOARD MEMBER 40.00 X X 100075 0 8047 MR M WAINWRIGHT FISHBURN JR CHAIRMAN 1.00 X X 0 0 0 MR JEFFERY JACOB VICE CHAIRMAN 1.00 X X 0 0 0 MR ALAN G LEVIN BOARD MEMBER 1.00 X 0 0 0 MR JAMES W NEWMAN BOARD MEMBER 1.00 X 0 0 0 DR KAREN BERNSTEIN BOARD MEMBER 1.00 X 0 0 0 MS KAY HOLCOMBE BOARD MEMBER 1.00 X 0 0 0 MS MARA G ASPINALL BOARD MEMBER 1.00 X 0 0 0 DR PAULA J OLSIEWSKI BOARD MEMBER 1.00 X 0 0 0 MR PETER BARTON HUTT BOARD MEMBER 1.00 X 0 0 0 MR SHAUN A KIRKPATRICK BOARD MEMBER 1.00 X 0 0 0 DR TIMOTHY R FRANSON BOARD MEMBER 1.00 X 0 0 0 DR TOMAS SALMONSON BOARD MEMBER 1.00 X 0 0 0 2973087 0 441084 60 0 1 0 ARIDHIA INFORMATICS LIMITED 163 BATH STREET GLASGOW UK IT SERVICES 726962 REPLICA ANALYTICS LTD 150 ELGIN STREET FLOOR 10 OTTAWA ONTARIO CA K2P 1L4 CONSULTANT 297070 LOTOS NILE PO BOX 90245 NASHVILLE TN 37209 PUBLIC RELATIONS 254344 PHARMASCOUTS 5580 LA JOLLA BOULEVARD 17 LA JOLLA CA 92037 CONSULTANT 174000 MARYNA KOLOCHAVINA NEHRINGSTR 33 BERLIN GM CONSULTANT 166988 7 18935171 4621865 32192 23557036 RESEARCH SUPPORT FEES 541700 11161610 11161610 OTHER REVENUE 900099 130798 130798 11292408 403834 403834 EARNINGS FROM SUBSIDIARY 900099 14004 14004 14004 35267282 11306412 0 403834 4116598 4116598 506606 506606 2549216 1421459 1127757 13659070 11979800 1679270 950723 843492 107231 1186216 1022677 163539 1126088 940449 185639 52818 512 52306 71025 71025 2758957 2325857 433100 329465 44352 285113 347789 22828 324961 1756423 1152812 603611 526615 419541 107074 698989 535732 163257 1070950 794698 276252 30852 4806 26046 102970 102970 DUES AND SUBSCRIPTIONS 101097 35965 65132 MISCELLANEOUS 65911 53601 12310 32008378 26221785 5786593 0 2618376 1343137 13932086 18603787 2336559 2673874 804595 1595768 46337 100962 209808 168068 72592 41740 151541 2367377 19962086 26726645 1958777 2558542 5896296 6796932 82473 2105301 7937546 11460775 X 12024540 15265870 12024540 15265870 19962086 26726645 X 3258904 -17574 X 0 1 X 1 1 1 X 10698823 12978641 17810315 23061454 23557036 88106269 10698823 12978641 17810315 23061454 23557036 88106269 8653378 79452891 215046 156753 5817 6633 403834 788083 88894352 37238127 0.89380 0.83360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 32008378 32008378 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 250000 250000 250000 250000 1000000 1500000 PART II-A, LINE 1B C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. C-PATH DOES EXPEND A MODEST AMOUNT OF TIME AND MONEY TO EDUCATE LEGISLATORS AND THEIR STAFF IN THE AREA OF DRUG DEVELOPMENT. 34898 34898 0 19837 16434 3403 155073 116736 38337 41740 DEPOSITS 12673 DUE FROM AFFILIATE 149012 INVESTMENT IN SUBSIDIARY -748 OTHER RECEIVABLES 122204 OPERATING LEASE ASSETS 2084236 2367377 OPERATING LEASE OBLIGATIONS 2105301 2105301 X PART X, LINE 2: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(1). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME. 1 NORTH AMERICA (CANADA) 0 0 BUSINESS/VENDOR SERVICES IT SERVICES, CONSULTING 338146 EUROPE (IRELAND, NETHERLANDS, SWEDEN, SWITZERLAND) 0 7 BUSINESS/VENDOR SERVICES IT SERVICES, CONSULTING, LICENSING, PAYROLL SERVICES 460651 EUROPE (UNITED KINGDOM) 0 1 GRANTS TO RECIPIENTS LOCATED IN REGION CLINICAL RESEARCH 506606 EUROPE (FRANCE, GERMANY, SLOVENIA, SWEDEN, UNITED KINGDOM) 0 0 PROGRAM SERVICES/BUSINESS SERVICES CLINICAL RESEARCH, CONSULTING, FILING FEES, EVENTS 1066452 EUROPE (IRELAND, NETHERLANDS, SWEDEN, SWITZERLAND) 0 0 INVESMENT -748 0 8 0 0 0 8 2371107 0 2371107 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUBAWARD 506606 WIRE TRANSFER 0 0 1 1 0 0 0 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. PART III ACCOUNTING METHOD: 1 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) 1900 CROWN COLONY DRIVE SUITE 310 QUINCY MA 02169 133223946 501(C)(3) 1517664 0 SUBAWARD JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DRIVE SUITE 350 TAMPA FL 33647 593187624 501(C)(3) 14789 0 SUBAWARD TUFTS MEDICAL CENTER INC 800 WASHINGTON STREET RF BOX 453 BOSTON MA 02111 043400617 501(C)(3) 86009 0 SUBAWARD INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN 9211 CORPORATE BOULEVARD SUITE 260 ROCKVILLE MD 20850 812076517 501(C)(3) 77657 0 SUBAWARD NORTHWESTERN UNIVERSITY 633 CLARK STREET ROOM G-547 EVANSTON IL 60208 362167817 501(C)(3) 54297 0 SUBAWARD SOCIETY OF CRITICAL CARE MEDICINE 35083 EAGLE WAY CHICAGO IL 60678 237104387 501(C)(3) 1377667 0 SUBAWARD JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 501(C)(3) 480752 0 SUBAWARD EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 160714 0 SUBAWARD UNIVERSITY OF ROCHESTER 265 CRITTENDEN BOULEVARD CU420694 ROCHESTER NY 14642 160743209 501(C)(3) 89728 0 SUBAWARD YALE UNIVERSITY 150 MUNSON STREET 3RD FLOOR NEW HAVEN CT 06520 060646973 STATE OF CONNECTICUT 125000 0 SUBAWARD UNIVERSITY OF ARIZONA PO BOX 41867 TUCSON AZ 85717 742652689 STATE OF ARIZONA 108444 0 SUBAWARD EVIDERA INC 7101 WISCONSIN AVENUE SUITE BETHESDA MD 20814 541759539 STATE OF MARYLAND 23877 0 SUBAWARD 9 12 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X X X X 0 0 0 0 0 0 0 1 0 MS KRISTEN SWINGLE COO & PRESIDENT 288447 0 21700 0 0 0 21814 0 24504 0 356465 0 0 0 DR KLAUS ROMERO CHIEF SCIENCE OFFICER 237099 0 4700 0 0 0 19482 0 15508 0 276789 0 0 0 MR KEVIN PERKINS CHIEF FINANCIAL OFFICER & TREASURER 220067 0 16875 0 0 0 19710 0 28104 0 284756 0 0 0 MR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 213419 0 12731 0 0 0 18049 0 11554 0 255753 0 0 0 DR STEPHEN COONS SENIOR VICE PRESIDENT THRU 03/31/23 219841 0 4326 0 0 0 17931 0 11028 0 253126 0 0 0 DR SUDHIR SIVAKUMARAN VICE PRESIDENT/EXECUTIVE DIRECTOR 204618 0 4201 0 0 0 17415 0 22383 0 248617 0 0 0 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 190519 0 3763 0 0 0 14727 0 15948 0 224957 0 0 0 DR SERGEY RAKHILIN EXECUTIVE DIRECTOR 188854 0 1520 0 0 0 11804 0 636 0 202814 0 0 0 MS SONYA EREMENCO EXECUTIVE DIRECTOR 186627 0 3740 0 0 0 15558 0 11797 0 217722 0 0 0 DR MARCO SCHITO EXECUTIVE DIRECTOR 178495 0 3530 0 0 0 14632 0 15150 0 211807 0 0 0 MS TERINA MARTINEZ EXECUTIVE DIRECTOR 178513 0 3500 0 0 0 14560 0 7229 0 203802 0 0 0 DR KANWALJIT SINGH EXECUTIVE DIRECTOR 174890 0 3523 0 0 0 11597 0 23363 0 213373 0 0 0 MR NICHOLAS KING EXECUTIVE DIRECTOR 169681 0 3400 0 0 0 14093 0 10450 0 197624 0 0 0 MR LEWIS BARBIERI CORPORATE SECRETARY 130896 0 3537 0 0 0 10846 0 13165 0 158444 0 0 0 PART I, LINE 7 CRITICAL PATH AWARDS VARIABLE COMPENSATION BASED ON PERFORMANCE AND WITH GUIDANCE FROM THE COMPENSATION COMMITTEE. X OFFICE FURNITURE 1 32192 THRIFT SALE VALUE 0 0 0 PART I, COLUMN (B): THE AMOUNT IN COLUMN B REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICES RDCA-DAP IS AN FDA-FUNDED INITIATIVE THAT WILL PROVIDE A CENTRALIZED AND STANDARDIZED INFRASTRUCTURE TO SUPPORT AND ACCELERATE RARE DISEASE CHARACTERIZATION WITH THE GOAL OF ACCELERATING THERAPY DEVELOPMENT. 2023 PROVED TO BE A BANNER YEAR FOR THE PLATFORM. THE PAST YEAR SAW 15 DISEASE DATA SETS ADDED TO THE PLATFORM TO MAKE IT 73 RARE DISEASE DATA SETS OVERALL, REPRESENTING OVER 34 DISEASE STATES (15 DISEASES ADDED IN 2023). THERE ARE NOW 445 PLATFORM USERS AND 26 ACTIVE WORKSPACES. ACTIVE AGREEMENTS NOW INCLUDE 35 DATA CONTRIBUTION AGREEMENTS, EIGHT NORD DATA CONTRIBUTION COVERSHEETS AND FOUR TASK FORCE AGREEMENTS. THERE WERE CONTINUED ADVANCEMENTS IN DATA AGGREGATION AND DISEASE MODELING IN THE DISEASE AREAS OF FRIEDREICH'S ATAXIA (FA) AND PROGRESSIVE SUPRANUCLEAR PALSY, AS WELL AS THE ESTABLISHMENT OF A CLINICAL TRIAL SIMULATOR TO INFORM TRIAL DESIGN IN FA. THIS YEAR ALSO MARKED THE RELEASE OF CRITICAL PATH ONTOLOGY (CPONT) APPLICATION, WHICH FACILITATES MAPPING AND LINKING BETWEEN DIFFERENT STANDARDIZED DATA VOCABULARIES. THERE WAS ALSO A SIGNIFICANT PAPER PUBLICATION, "THE FUTURE OF RARE DISEASE DRUG DEVELOPMENT: THE RARE DISEASE CURES ACCELERATOR DATA ANALYTICS PLATFORM (RDCA-DAP)" IN THE JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. ANOTHER SIGNIFICANT PUBLICATION WAS THAT OF EDUCATION MODULES 1-3. "RARE DISEASE DRUG DEVELOPMENT: WHAT PATIENTS AND ADVOCATES NEED TO KNOW." RDCA-DAP MADE SIGNIFICANT CONTRIBUTIONS TO THE COMMUNITY IN PERSON; THE 2023 RARE AND ORPHAN DISEASE CONFERENCE HAD 282 REGISTRANTS AND 202 ATTENDEES, INCLUDING 53 EXTERNAL SPEAKERS AND PANELISTS ACROSS ACADEMIA, GOVERNMENT/REGULATORY, INDUSTRY, NONPROFITS, AND PATIENTS/CAREGIVERS. LASTLY, THE PROGRAM MADE A SIGNIFICANT IMPACT ON PROFESSIONAL DEVELOPMENT WITH FOUR WEBINARS HELD AS PART OF ITS PROFESSIONAL DEVELOPMENT SERIES, WITH 760 REGISTRANTS AND 441 ATTENDEES. FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICES CURE DRUG REPURPOSING COLLABORATORY (CDRC) WAS FOUNDED IN 2020 AND IS DESIGNED TO CAPTURE REAL-WORLD CLINICAL OUTCOME DATA TO ADVANCE DRUG REPURPOSING AND INFORM FUTURE CLINICAL TRIALS FOR DISEASES OF HIGH UNMET MEDICAL NEED. THE PAST YEAR REPRESENTED SOME INCREDIBLE PROGRESS FROM THE COLLABORATORY. CDRC ASSISTED IN THE DEVELOPMENT, CONSENSUS, FINALIZATION, AND DEPLOYMENT OF A SARCOMA CLINICAL CASE REPORT FORM FOR THE CURE ID APP WITH INPUT FROM MULTIPLE STAKEHOLDERS, AND ALSO INITIATED A CONTRACT WITH PROGRAM PARTNER XCURES TO EXTRACT DATA FROM SARCOMA PATIENT EHRS FOR PECOMA CASES. STUDENTS FROM CLEMSON UNIVERSITY SCHOOL OF MEDICINE AND INTERNS FROM CDRC ALSO HAD THE OPPORTUNITY TO EXTRACT PECOMA CASES FROM THE LITERATURE TO CURE ID, WHILE THE PROGRAM ESTABLISHED AND LED MONTHLY SARCOMA WORKGROUP CALLS FOR PATIENTS, CLINICIANS, AND FDA OCE (ONCOLOGY CENTERS OF EXCELLENCE) TO DEVELOP A SARCOMA PILOT WITHIN CURE ID. CDRC PARTNERED WITH HEHEALTH TO REVIEW AND EDIT THE MPOX CRF ON CURE ID APP TO PROMOTE OUTREACH TO PATIENTS. THE TEAM CREATED AN INTERNATIONAL STI SURVEILLANCE GROUP UNDER THE AUSPICES OF WHO, WITH EXISTING SURVEILLANCE EFFORTS IN THE U.S., CANADA, AND THE UK TO PARTNER ON A PROJECT TO IDENTIFY REPURPOSED DRUGS FOR NEISSERIA GONORRHEA WITH ADDITIONAL COUNTRIES AS OBSERVERS. THIS GROUP HELPED CREATE THE CRF FOR NEISSERIA GONORRHEA AND ORGANIZED A MONTHLY LONG COVID CLINICAL THINK TANK CALL SERIES CONSISTING OF 27 CLINICAL TRIALISTS REGULATORS, ACADEMICIANS AND FOUNDATIONS ACROSS THE U.S., CANADA, AND EUROPE TO REVIEW AND DISCUSS CHALLENGES IN SETTING UP AND DESIGNING CLINICAL TRIALS FOR THIS DISEASE. FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICES CP-RND WAS FOUNDED IN SEPTEMBER 2022 TO LEAD COLLABORATIONS THAT ADVANCE TREATMENTS TO IMPROVE THE LIVES OF THOSE AFFECTED BY RARE NEURODEGENERATIVE DISEASES, INCLUDING ALS. CP-RND HAD MAJOR HIGHLIGHTS IN ITS FIRST FULL YEAR AS A C-PATH CONSORTIUM. IN REGARD TO ITS PATIENT-FOCUSED DRUG DEVELOPMENT PROCESS, THE GROUP WAS ACTIVE IN ITS ENGAGEMENT WITH PEOPLE LIVING WITH DISEASES, ITS COORDINATION WITH ACCELERATING MEDICINE PARTNERSHIP (AMP) EFFORTS, AND IN THE FORMATION OF A PEOPLE WITH LIVED EXPERIENCES (PWLE) GROUP TO GIVE AND RECEIVE FEEDBACK ON ALS-RELATED PROJECTS. FROM A DATA PERSPECTIVE, CP-RND REVIEWED OVER 70 LARGE DATABASES, WITH A PRIORITY LISTING CREATED AND SHARED WITH AMP ALS. THE GROUP ALSO SUMMARIZED RESULTS OF AROUND 700 STUDIES FROM CLINICALTRIALS.GOV SEARCHES. PROGRESS FOR DATA DICTIONARY COLLECTION AND DATA SHARE AGREEMENTS REMAIN ONGOING. FINALLY, CP-RND'S SCIENTIFIC CONTRIBUTIONS ARE REFLECTED BY ITS EFFORTS TO REVIEW AND COLLABORATE WITH KEY OPINION LEADERS REGARDING NFL/TDP43 AND OTHER POTENTIAL BIOMARKERS FOR USE IN ALS CLINICAL TRIALS. FORM 990, PART VI, SECTION A, LINE 2 JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S CFO, PRESIDENT/COO, CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. PERIODICALLY, THE COMMITTEE REQUESTS A COMPENSATION ANALYSIS TO DETERMINE IF EMPLOYEE COMPENSATION HAS REMAINED WITHIN MARKET RANGE OR IF ADJUSTMENTS ARE REQUIRED. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/COO. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. FORM 990, PART XI, LINE 9: BOOK/TAX DIFFERENCE - OPERATING LEASE -17,574. CRITICAL PATH INSTITUTE STICHTING 1083 HN AMSTERDAM AMSTERDAM NL EDUCATION AND RESEARCH IN EUROPE TO ACCELERATE DEVELOPMENT OF NEW THERAPIES NL 0 82200 CRITICAL PATH INSTITUTE CRITICAL PATH INSTITUTE LTD 33 SIR JOHN ROGERSONS QUAY DUBLIN EI EDUCATION AND RESEARCH IN EUROPE TO ACCELERATE DEVELOPMENT OF NEW THERAPIES EI CRITICAL PATH INSTITUTE STICHTING C 364512 1.00000 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CRITICAL PATH INSTITUTE LTD D 149011 END OF YEAR BALANCE